Organovo Holdings, Inc. (0R02.L)
USD 0.26
(2.08%)
USD 0.26
(2.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.74 Million USD | -44.86% |
| 2022 | 4.98 Million USD | 61.45% |
| 2021 | 3.08 Million USD | 328.16% |
| 2020 | 721 Thousand USD | -60.17% |
| 2019 | 1.81 Million USD | -58.15% |
| 2018 | 4.32 Million USD | -17.48% |
| 2017 | 5.24 Million USD | -23.13% |
| 2016 | 6.81 Million USD | 26.38% |
| 2015 | 5.39 Million USD | 12.56% |
| 2014 | 4.79 Million USD | 152.0% |
| 2013 | 1.9 Million USD | -91.37% |
| 2012 | 22.05 Million USD | 0.0% |
| 2010 | 10.69 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.8 Million USD | 2.18% |
| 2023 FY | 2.74 Million USD | -44.86% |
| 2023 Q2 | 2.7 Million USD | -9.23% |
| 2023 Q1 | 2.98 Million USD | -40.21% |
| 2023 Q4 | 2.74 Million USD | 1.82% |
| 2023 Q3 | 2.69 Million USD | -0.22% |
| 2022 Q1 | 2.89 Million USD | -6.32% |
| 2022 FY | 4.98 Million USD | 61.45% |
| 2022 Q4 | 4.98 Million USD | 78.64% |
| 2022 Q3 | 2.79 Million USD | -3.93% |
| 2022 Q2 | 2.9 Million USD | 0.41% |
| 2021 Q1 | 964 Thousand USD | 33.7% |
| 2021 Q2 | 1.67 Million USD | 73.76% |
| 2021 FY | 3.08 Million USD | 328.16% |
| 2021 Q4 | 3.08 Million USD | -18.81% |
| 2021 Q3 | 3.8 Million USD | 126.99% |
| 2020 Q2 | 657 Thousand USD | -21.32% |
| 2020 FY | 721 Thousand USD | -60.17% |
| 2020 Q1 | 835 Thousand USD | -53.87% |
| 2020 Q3 | 829 Thousand USD | 26.18% |
| 2020 Q4 | 721 Thousand USD | -13.03% |
| 2019 Q4 | 1.81 Million USD | -23.24% |
| 2019 Q1 | 7.31 Million USD | 69.06% |
| 2019 Q2 | 6.69 Million USD | -8.4% |
| 2019 Q3 | 2.35 Million USD | -64.8% |
| 2019 FY | 1.81 Million USD | -58.15% |
| 2018 Q3 | 4.01 Million USD | 6.79% |
| 2018 Q2 | 3.75 Million USD | 0.51% |
| 2018 Q1 | 3.73 Million USD | -28.72% |
| 2018 Q4 | 4.32 Million USD | 7.86% |
| 2018 FY | 4.32 Million USD | -17.48% |
| 2017 FY | 5.24 Million USD | -23.13% |
| 2017 Q4 | 5.24 Million USD | 5.81% |
| 2017 Q3 | 4.95 Million USD | 2.06% |
| 2017 Q2 | 4.85 Million USD | 9.23% |
| 2017 Q1 | 4.44 Million USD | -34.83% |
| 2016 Q1 | 4 Million USD | -25.78% |
| 2016 Q4 | 6.81 Million USD | 30.44% |
| 2016 Q3 | 5.22 Million USD | 3.53% |
| 2016 Q2 | 5.04 Million USD | 26.1% |
| 2016 FY | 6.81 Million USD | 26.38% |
| 2015 FY | 5.39 Million USD | 12.56% |
| 2015 Q4 | 5.39 Million USD | -1.86% |
| 2015 Q3 | 5.49 Million USD | -0.51% |
| 2015 Q2 | 5.52 Million USD | 5.36% |
| 2015 Q1 | 5.24 Million USD | 9.41% |
| 2014 Q2 | 3.11 Million USD | 0.78% |
| 2014 FY | 4.79 Million USD | 152.0% |
| 2014 Q4 | 4.79 Million USD | 27.47% |
| 2014 Q1 | 3.09 Million USD | 62.46% |
| 2014 Q3 | 3.76 Million USD | 20.75% |
| 2013 Q2 | 2.95 Million USD | -61.11% |
| 2013 Q3 | 2.91 Million USD | -1.42% |
| 2013 FY | 1.9 Million USD | -91.37% |
| 2013 Q4 | 1.9 Million USD | -34.73% |
| 2013 Q1 | 7.6 Million USD | -9.59% |
| 2012 Q1 | 81.46 Million USD | 67.54% |
| 2012 Q3 | 22.05 Million USD | -39.53% |
| 2012 Q2 | 36.46 Million USD | -55.24% |
| 2012 Q4 | 8.4 Million USD | -61.88% |
| 2012 FY | 22.05 Million USD | 0.0% |
| 2011 Q1 | 10.69 Thousand USD | 1025.47% |
| 2011 Q2 | 32.19 Thousand USD | 201.07% |
| 2011 Q3 | 74.02 Thousand USD | 129.95% |
| 2011 Q4 | 48.62 Million USD | 65591.71% |
| 2010 FY | 10.69 Thousand USD | 0.0% |
| 2010 Q4 | 950.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 99.209% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 99.426% |
| Codexis, Inc. | 49.94 Million USD | 94.498% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | 94.323% |